The FDA has approved Treanda (bendamustine HCl injection, from Cephalon) for the treatment of indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within six months of treatment with a rituximab regimen. This approval is based on a trial of 100 Treanda-treated NHL patients who had an overall response rate of 74%, with treatment responses lasting a median of 9.2 months and survival without disease progression lasting a median of 9.3 months.

Treanda is already approved for the treatment of chronic lymphocytic leukemia (CLL).

For more information call (800) 896-5855 or visit